Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
29 March 2021Website:
http://www.designtx.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 20:02:35 GMTDividend
Analysts recommendations
Institutional Ownership
DSGN Latest News
Design Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Design focuses on therapies to treat neurological disorders. The company said it has enough cash to fund operations through 2026.
Shares of Design Therapeutics Inc. DSGN dropped 45% in premarket trading Tuesday after the biopharma company reported mixed results from an early-stage trial of a treatment for Friedreich ataxia, a genetic neuromuscular disease. The phase 1 trial of the treatment, DT-216, confirmed clinical activity in patients with the disease but also found injection-site reactions, the company said in a release late Monday.
CARLSBAD, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that management will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 3:30 p.m. ET in NYC.
Treatment with DT-168 Eye Drops Reduced Nuclear Foci and Significantly Improved Mis-Splicing In Vitro Company On-track to Submit Investigational New Drug Application for DT-168 in the Second Half of 2023 CARLSBAD, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company's novel GeneTAC™ small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy (FECD), will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting (ARVO 2023), which is being held in New Orleans from April 23-27, 2023.
Sorry to be the bearer of bad news, but Design Therapeutics (NASDAQ: DSGN ) has good intentions and less-than-stellar financials. Design Therapeutics may be a pioneer in the field of genomic medicine, and that's commendable.
What type of business is Design Therapeutics?
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
What sector is Design Therapeutics in?
Design Therapeutics is in the Healthcare sector
What industry is Design Therapeutics in?
Design Therapeutics is in the Biotechnology industry
What country is Design Therapeutics from?
Design Therapeutics is headquartered in United States
When did Design Therapeutics go public?
Design Therapeutics initial public offering (IPO) was on 29 March 2021
What is Design Therapeutics website?
https://www.designtx.com
Is Design Therapeutics in the S&P 500?
No, Design Therapeutics is not included in the S&P 500 index
Is Design Therapeutics in the NASDAQ 100?
No, Design Therapeutics is not included in the NASDAQ 100 index
Is Design Therapeutics in the Dow Jones?
No, Design Therapeutics is not included in the Dow Jones index
When does Design Therapeutics report earnings?
The next expected earnings date for Design Therapeutics is 14 August 2024